Malignant Melanoma S3-Guideline "Diagnosis, Therapy and Follow-up of Melanoma"

被引：202

作者：

Pflugfelder, Annette ^{[1
]}

Kochs, Corinna ^{[2
]}

Blum, Andreas

Capellaro, Marcus ^{[3
]}

Czeschik, Christina ^{[2
]}

Dettenborn, Therese ^{[4
]}

Dill, Dorothee

Dippel, Edgar ^{[5
]}

Eigentler, Thomas ^{[1
]}

Feyer, Petra ^{[6
]}

Follmann, Markus ^{[7
]}

Frerich, Bernhard ^{[8
]}

Ganten, Maria-Katharina ^{[9
]}

Gaertner, Jan ^{[10
]}

Gutzmer, Ralf ^{[11
]}

Hassel, Jessica ^{[12
]}

Hauschild, Axel ^{[13
]}

Hohenberger, Peter ^{[14
]}

Huebner, Jutta ^{[15
]}

Kaatz, Martin ^{[16
]}

Kleeberg, Ulrich R. ^{[17
]}

Koelbl, Oliver ^{[18
]}

Kortmann, Rolf-Dieter ^{[19
]}

Krause-Bergmann, Albrecht ^{[4
]}

Kurschat, Peter ^{[20
]}

Leiter, Ulrike ^{[1
]}

Link, Hartmut ^{[21
]}

Loquai, Carmen ^{[22
]}

Loeser, Christoph ^{[5
]}

Mackensen, Andreas ^{[23
]}

Meier, Friedegund ^{[1
]}

Mohr, Peter ^{[3
]}

Moehrle, Matthias ^{[1
,24
]}

Nashan, Dorothee ^{[25
]}

Reske, Sven ^{[26
]}

Rose, Christian

Sander, Christian ^{[27
]}

Satzger, Imke ^{[11
]}

Schiller, Meinhard ^{[28
]}

Schlemmer, Heinz-Peter ^{[9
]}

Strittmatter, Gerhard ^{[29
]}

Sunderkoetter, Cord ^{[28
]}

Swoboda, Lothar ^{[30
]}

Trefzer, Uwe ^{[31
]}

Voltz, Raymond ^{[10
]}

Vordermark, Dirk ^{[32
]}

Weichenthal, Michael ^{[13
]}

Werner, Andreas ^{[33
]}

Wesselmann, Simone ^{[7
]}

Weyergraf, Ansgar J. ^{[34
]}

机构：

[1] Univ Tubingen Hosp, Dept Dermatol, Tubingen, Germany

[2] Univ Hosp Essen, Dept Dermatol, Essen, Germany

[3] Assoc Dermatol Prevent, Buxtehude, Germany

[4] Fachklin Hornheide, Munster, Germany

[5] Ludwigshafen Hosp, Skin Canc Ctr, Dept Dermatol, Ludwigshafen, Germany

[6] Vivantes Clin Neukolln, Clin Radiotherapy & Radiooncol, Berlin, Germany

[7] German Canc Soc Berlin, Berlin, Germany

[8] Univ Rostock, Dept Oral & Maxillofacial Surg, D-18055 Rostock, Germany

[9] German Canc Res Ctr, Dept Radiol, Heidelberg, Germany

[10] Univ Hosp Cologne, Dept Palliat Med, Cologne, Germany

[11] Hannover Med Sch, Dept Dermatol & Allergy, Hannover, Germany

[12] German Canc Res Ctr, Heidelberg, Germany

[13] Univ Kiel, Dept Dermatol, Kiel, Germany

[14] Univ Mannheim, Med Ctr, Div Surg Oncol & Thorac Surg, Mannheim, Germany

[15] Goethe Univ Frankfurt, D-60054 Frankfurt, Germany

[16] SRH Waldklinikum Gera Gmbh, Dept Dermatol & Allergol, Gera, Germany

[17] HOPA, Hamburg, Germany

[18] Univ Hosp Regensburg, Dept Radiotherapy, Regensburg, Germany

[19] Univ Leipzig, Dept Radiat Therapy, D-04109 Leipzig, Germany

[20] Univ Hosp Cologne, Dept Dermatol & Venereol, Cologne, Germany

[21] Westpfalz Klinikum, Med Clin 1, Kaiserslautern, Germany

[22] Johannes Gutenberg Univ Mainz, Dept Dermatol, Mainz, Germany

[23] Univ Erlangen Nurnberg, Dept Internal Med Hematol Oncol 5, Erlangen, Germany

[24] Praxisklin Tubingen Haut & Venen, Tubingen, Germany

[25] Klinikum Dortmund gGmbH, Dept Dermatol, Dortmund, Germany

[26] Univ Clin, Dept Nucl Med, Ulm, Germany

[27] Asklepios Klin St Georg, Klin Dermatol & Allergol, Hamburg, Germany

[28] Univ Hosp Munster, Dept Dermatol, Munster, Germany

[29] Fachklin Hornheide, Dept Psychosocial Oncol, Munster, Germany

[30] German Soc Thorac Surg, Berlin, Germany

[31] Univ Hosp Charite Berlin, Dept Dermatol, Berlin, Germany

[32] Univ Klinikum Halle, Dept Radiooncol, Halle, Germany

[33] Tumor Ctr Rhineland Palatinate, Mainz, Germany

[34] Bad Bentheim Hosp, Dept Dermatol & Allergy, Bad Bentheim, Germany

[35] Univ Clin, Dept Neurooncol, Heidelberg, Germany

来源：

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2013年 / 11卷

关键词：

SENTINEL LYMPH-NODE; QUALITY-OF-LIFE; HIGH-RISK MELANOMA; RANDOMIZED PHASE-III; POSITRON-EMISSION-TOMOGRAPHY; AMERICAN-JOINT-COMMITTEE; POLYMERASE-CHAIN-REACTION; ISOLATED LIMB PERFUSION; PRIMARY CUTANEOUS MELANOMA; ISOLATED HEPATIC PERFUSION;

D O I：

10.1111/ddg.12113_suppl

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

This first German evidence-based guideline for cutaneous melanoma was developed under the auspices of the German Dermatological Society (DDG) and the Dermatologic Cooperative Oncology Group (DeCOG) and funded by the German Guideline Program in Oncology. The recommendations are based on a systematic literature search, and on the consensus of 32 medical societies, working groups and patient representatives. This guideline contains recommendations concerning diagnosis, therapy and follow-up of melanoma. The diagnosis of primary melanoma based on clinical features and dermoscopic criteria. It is confirmed by histopathologic examination after complete excision with a small margin. For the staging of melanoma, the AJCC classification of 2009 is used. The definitive excision margins are 0.5 cm for in situ melanomas, 1 cm for melanomas with up to 2 mm tumor thickness and 2 cm for thicker melanomas, they are reached in a secondary excision. From 1 mm tumor thickness, sentinel lymph node biopsy is recommended. For stages II and III, adjuvant therapy with interferon-alpha should be considered after careful analysis of the benefits and possible risks. In the stage of locoregional metastasis surgical treatment with complete lymphadenectomy is the treatment of choice. In the presence of distant metastasis mutational screening should be performed for BRAF mutation, and eventually for CKIT and NRAS mutations. In the presence of mutations in case of inoperable metastases targeted therapies should be applied. Furthermore, in addition to standard chemotherapies, new immunotherapies such as the CTLA-4 antibody ipilimumab are available. Regular follow-up examinations are recommended for a period of 10 years, with an intensified schedule for the first three years.

引用

页码：1 / 116

页数：116

共 740 条

[31]

Auge JM, 2005, ANTICANCER RES, V25, P1779

[32]

Augustin M, 2005, ARZNEIMITTELFORSCH, V55, P38

[33]

AUGUSTIN M, 1997, Z HAUTKRANKHEITEN, V72, P333

[34] Utility of FDG PET/CT and Brain MRI in Melanoma Patients with Increased Serum S-100B Level During Follow-up [J].

Aukema, Tjeerd S. ;

Olmos, Renato A. Valdes ;

Korse, Catharina M. ;

Kroon, Bin B. R. ;

Wouters, Michel W. J. M. ;

Vogel, Wouter V. ;

Bonfrer, Johannes M. G. ;

Nieweg, Omgo E. .

ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (06) :1657-1661

[35] Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma:: A phase III study [J].

Avril, MF ;

Aamdal, S ;

Grob, JJ ;

Hauschild, A ;

Mohr, P ;

Bonerandi, JJ ;

Weichenthal, M ;

Neuber, K ;

Bieber, T ;

Gilde, K ;

Porta, VG ;

Fra, J ;

Bonneterre, J ;

Saïag, P ;

Kamanabrou, D ;

Pehamberger, H ;

Sufliarsky, J ;

Larriba, JLG ;

Scherrer, A ;

Menu, Y .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1118-1125

[36] Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma - An analysis of 3661 patients from a single center [J].

Azzola, MF ;

Shaw, HM ;

Thompson, JF ;

Soong, SJ ;

Scolyer, RA ;

Watson, GF ;

Colman, MH ;

Zhang, YT .

CANCER, 2003, 97 (06) :1488-1498

[37] Teaching communication skills to medical oncology fellows [J].

Back, AL ;

Arnold, RM ;

Tulsky, JA ;

Baile, WF ;

Fryer-Edwards, KA .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2433-2436

[38] The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma [J].

Bafaloukos, D ;

Tsoutsos, D ;

Fountzilas, G ;

Linardou, H ;

Christodoulou, C ;

Kalofonos, HP ;

Briassoulis, E ;

Panagiotou, P ;

Hatzichristou, H ;

Gogas, H .

MELANOMA RESEARCH, 2004, 14 (04) :289-294

[39] Ultrasonography or palpation for detection of melanoma nodal invasion: a meta-analysis [J].

Bafounta, ML ;

Beauchet, A ;

Chagnon, S ;

Saiag, P .

LANCET ONCOLOGY, 2004, 5 (11) :673-680

[40]

Bafounta ML, 2001, ARCH DERMATOL, V137, P1343

← 1 2 3 4 5 6 7 8 9 10 →